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Abstract 
 
EPs® 7630 is an aqueous-ethanolic extract of the roots of Pelargonium sidoides, employed in the 
treatment of upper respiratory tract infections. Its anti-infective activity is supposed to be associated 
with the activation of the nonspecific immune system. Using Leishmania major GFP-infected murine 
BMMΦ, the NO production of EPs® 7630-activated macrophages was correlated with the reduction of 
the GFP signal measured at single cell levels using flow cytometry. The anti-infectious effect of EPs® 
7630 (3–10 μg/mL) on its own (NO production: 4–13 μM; signal reduction: 25– 73%) was less 
prominent than that in combination with IFN-γ (100 U/mL) (NO production: 20– 27 μM; signal 
reduction: 35–78%). Furthermore, supernatants of EPs® 7630-stimulated BMMΦ (10 μg/mL) 
significantly reduced the cytopathic effect of EMCV on L929 fibroblasts (antiviral activity 80 U/mL) 
when compared with an IFN-γ standard (100 U/mL). Direct addition of EPs® 7630 to L929 did not 
mediate cytoprotective effects. The antiviral components induced in BMMΦ by EPs® 7630 remain to 
be identified. Detection of any IFNs by ELISA was unsuccessful, which may be due to their very low 
concentrations in cell supernatants. The current data provide convincing support for the induction of 
anti-infectious responses by EPs® 7630. 
 
 
Abbreviations 
 
BMMΦ: bone marrow-derived macrophages 
rINF: recombinant interferon 
EMCV: encephalomyocarditis virus 
L-NMMA: NG-monomethyl-L-arginine 
CPE: cytopathic effect 
GFP: green fluorescent protein 
PI: propidium iodide 
 
 
Introduction 
 
EPs® 7630 is an aqueous-ethanolic extract from the roots of Pelargonium sidoides (Geraniaceae), 
exclusively contained in Umckaloabo®, an herbal medicinal product marketed by Spitzner 
Arzneimittel, Ettlingen, Germany. Although a number of clinical studies documented the effectiveness 
and safety of this herbal remedy for the treatment of upper respiratory tract infections [1–6], its mode 
of action is still insufficiently understood. We recently reported that murine BMMΦ incubated with 30 
μg/mL of EPs® 7630 for 6 h showed a significant increase in the production of proinflammatory 
mediators such as nitric oxide (NO), IL-1α, TNF-α and IL-12. In addition, this effect was significantly 
enhanced in BMMΦ infected with Listeria monocytogenes and exposed to EPs® 7630 [7].  
 
The present paper is a continuation of our work and provides further insight into the anti-infectious 
principles of EPs® 7630. BMMΦ treated with EPs® 7630 (10 μg/mL)were effectively activated to kill 
intracellular GFP-transfected Leishmania major parasites (L. major GFP) as assessed by a recently 
established FACS-based method [8]. Taking into account previous studies [9], this finding suggests 
that EPs® 7630 exerts its anti-infectious activity against a broad spectrum of pathogens. Furthermore, 
significant inhibition of the cytopathic effect of EMCV on a sensitive murine fibroblast L929 cell line 
gives credence to an improved antiviral protection in afflicted patients treated with this herbal 
medicine. 
 
 
Material and Methods 
 
Plant material 
EPs® 7630 (batch Ch.-No. 007) is an aqueous ethanolic (11% m/m) extract of Pelargonium sidoides 
DC roots with a yield of 9–11% [10] and was kindly provided by Dr. Willmar Schwabe GmbH & Co. 
The dried extract was dissolved in DMSO (Merck) at a concentration of 20 mg/mL for use as stock 
solution. 
 
Mice 
Six- to 12-week-old female C57BL/6 mice were bred at and supplied by Zentrale Versuchtierzucht, 
Federal Institute for Risk Assessment (BfR), Berlin, Germany. Animal care and the experimental 
procedures were in accordance with the institutional guidelines and German law. The animal 
experiments were approved by the Landesamt für Gesundheit und Soziales, Berlin on April 27, 2004 
under the number 01707/04. 
 
Pathogens and cell lines 
Green fluorescent protein transfected L. major, strain LT 52, clone CC-1pXG-GFP (L. major GFP; 
[11]), stable under the influence of geneticin, were kindly provided by S.M. Beverley (Department of 
Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA). L. major 
GFP were cultured in Leishmania growth medium consisting of RPMI 1640 medium (Gibco-
Invitrogen), 5% heat-inactivated fetal calf serum (FCS), penicillin (100 U/mL; PAA Laboratories), 
streptomycin (100 μg/ mL; PAA), Na-pyruvate (10 mM; Sigma-Aldrich Chemie), HEPES (25 mM; 
Gibco), Geneticin (25 μg/mL; G418, Gibco; only with L. major GFP), and hemin (0.25% v/v solution B 
of Hosmem II medium; [12]) at 25°C in a humidified atmosphere with 5% CO2. Murine EMC-virus 
(single stranded RNA poliovirus, Picornaviridae) and the murine L929 fibroblast cell line, selected for 
IFNsensitivity, were a kind gift of the late Dr. M.L. Lohmann-Matthes (Fraunhofer Institut für 
Toxikologie, Hannover, Germany).  
 
Bone marrow derived macrophages (BMMΦ)  
Micewere killed by cervical dislocation and bone marrowwas obtained by flushing the femura and 
tibiae with cold Ca2+- and Mg2 +-free phosphate-buffered saline (PBS). BMMΦ were produced as 
described previously [13] with minor modifications. Briefly, the pooled bone marrow precursor cells 
were matured in polystyrene petri dishes (Sarstedt) for 6–8 days in RPMI 1640 medium supplemented 
with 10% heat-inactivated fetal calf serum (Bio Whittaker), 5% heat-inactivated horse serum (Gibco), 
15% fibroblast (GM-CSF transfected L929 cells) conditioned medium, penicillin (100 U/mL), 
streptomycin (100 μg/mL), D-glucose (20 mM, Sigma), Na-pyruvate (10 mM), and HEPES (25 mM) at 
37°C in a humidified atmosphere with 5% CO2. For harvesting, the medium was replaced twice by cold 
PBS, thereby removing most nonadherent cells and debris. BMMΦ were chilled to 4°C for 1 h, rinsed 
off the plastic with a 5-mL pipette and washed by centrifugation (250 × g, 10 min, 4°C). The viable 
cells, as assessed by trypan-blue exclusion, were counted and kept at 4°C until use. 
 
Fibroblast-virus protection assay (IFN activity) 
BMMΦ (1.0 × 106 cells/mL) were incubated for 24 h with EPs® 7630 (10, 5, 1 μg/mL, respectively), in 
R5 medium consisting of RPMI 1640 (Gibco-Invitrogen) plus 5% heat-inactivated fetal calf serum 
(FCS), HEPES (25 mM, Gibco), Na-pyruvat (10 mM, Sigma- Aldrich). Untreated cells served as the 
negative control, LPS (1 ng/ mL; obtained from Escherichia coli; Sigma-Aldrich) treated BMMΦ as the 
positive control, and DMSO (0.5%) as the vehicle control. Experimental culture supernatants were 
collected and stored at −70°C until use. Dead cells were detected by flow cytometry after staining with 
PI [14] (PI-positive cells were below 10% in all experiments). Interferon activity was assessed by 
observing the protection of murine L929 fibroblasts against the cytopathic effect induced by infection 
with EMCV. For this, a monolayer of EMCV- and IFNsensitive murine L929 fibroblasts (1.0 × 104 
cells/well) was incubated overnight in R5 medium alone (negative control) or with serial 1:2 dilutions of 
the experimental culture supernatants described above. Serial 1:2 dilutions of murine rIFN-γ (100 
U/mL; Genentech) served as a reference for cytoprotection. Then 100 μL of a pretested EMCV 
suspension (3680 PFU/mL in R 2.5 medium consisting of RPMI 1640 plus 2.5% heat-inactivated FCS, 
25mM HEPES, 10mM Na-pyruvat, 100 μg/mL streptomycin and 100 U/mL penicillin [both PAA 
Laboratories]) was added to each well and cell destruction was monitored microscopically in the 
control samples. At this point, when non-protected cells had disintegrated due to the cytopathic effect 
of the virus, the relative number of viable cells per well was assessed colorimetrically by the crystal 
violet method. For this, cells were fixed and stained for 30 min using crystal violet solution (0.1% 
crystal violet, 2% ethanol, 10% formaldehyde in PBS). Excess of the dyewaswashed off with water. 
After drying, the remaining dye crystals were dissolved in acetic acid (33% acetic acid in PBS) and the 
preparations subjected to spectral photometric analysis. Relative optical density, correlating with the 
relative amount of viable cells/well was measured at 595 nm using an ELISA reader (SpetraFluor) and 
Magellan V5.03 software (both Tecan). The cytoprotective effect was compared to that of recombinant 
murine IFN-γ. Antiviral activity was expressed in U/mL, defined as reciprocal value of the supernatant 
dilution that would inhibit 50% of the cytopathic effect. These values were correlated with the IFN 
standard to account for any fluctuation in assay sensitivity. This functional assay does not discriminate 
between IFN-α, IFN-β, and IFN-γ [15]. In a modified procedure, L929 fibroblasts were directly 
incubated with EPs® 7630 samples overnight. 
 
Interferon ELISA 
Production of murine IFN-α (αA α1 α4 α5 α6, and α9 according to the manufacturer) and IFN-β (PBL 
Biomedical Laboratories) was determined by ELISA according to the manufacturer’s protocol, with 
detection limits of ca. 16 pg/mL. For IFN-γ (clone R4-6A2 for coating; biotinylated clone AN-18 for 
detection), high protein binding 96-well polystyrene microtiter plates (Immunmodule F16 Maxisorb; 
Nunc) were coated overnight at 4°C with antibody and washed four times with PBS containing 0.05% 
(v/v) Tween-20. Protein binding capacity was saturated using PBS containing 10% FCS (v/v) for 1 h at 
room temperature. Serial dilutions of recombinant standard cytokine and testsupernatants, 
respectively, were loaded and incubated overnight at 4°C, followed by the addition of a biotinylated 
detecting antibody. After 1 h at room temperature, streptavidin-coupled horseradish peroxidase was 
added, and cells incubated for one more hour. Then microtiter plates were washed repeatedly to 
minimize background and a 3,3′,5,5′-tetramethylbenzidine (0.1 mg/ mL; Sigma-Aldrich) substrate 
solution was added. After 15 min, the conversion into a light blue color by the horseradish peroxidase 
was stopped by adding 2 N H2SO4 (100 μL/well). The absorbance was read immediately at 450nm 
using an ELISA reader (SpectraFluor) and Magellan V5.03 software (Tecan). 
 
In vitro infection of BMMΦ with Leishmania GFP parasites 
In vitro infection of BMMΦ with L. major GFP and activation of macrophages with IFN-γ (100 U/mL) 
and IFN-γ (100 U/mL) plus LPS (10 ng/mL) have been fully described elsewhere [8]. Noninfected and 
non-treated as well as infected non-treated BMMΦ were used as negative controls and amphotericin B 
(Sigma Aldrich), a standard antileishmanial drug, was used as the positive control of parasite killing. 
For treatment of cells, R10 medium was completely replaced by 2 mL R10 medium containing different 
concentrations (0.1– 10 μg/mL) of EPs® 7630. After 48 h of incubation, BMMΦ were pelleted (200 × g, 
10 min, 4°C), the experimental culture supernatants were collected and stored at − 70°C until use. 
 
Flow cytometric measurements of Leishmania 
GFP-infected BMMΦ 
After treatment, cells were resuspended in 300 μL of PBS and stored on ice to facilitate detachment of 
the remaining adherent cells. To discriminate dead from living cells, propidium iodide (PI; Sigma) 
solution was added ca. 30 s before FACS measurement, giving a final concentration of 0.33 μg PI/mL. 
Information on the rate of infection was obtained by comparing the GFP-signal with that of noninfected 
cells. A total of 30000 events were counted using a FACS Calibur cytometer and CellQuest Pro 
software (both BD Biosciences). 
 
Griess-assay for NO-production by activated BMMΦ 
After incubating, the supernatants of EPs® 7630 treated BMMΦ cultures collected as a source of 
secreted NO were subjected to the Griess assay for determining the total nitric oxides produced by 
activated BMMΦ [16]. For this, 100 μL of the supernatant were mixed with equal volumes of freshly 
prepared Griess reagents [1 :1 v/v mixture of 1% sulphanilamide, 0.1% N-(1-naphthyl)ethylendiamine 
dihydrochloride in 3% H3PO4 (Sigma Aldrich)]. After 5 min at room temperature, the absorbance was 
measured at 550nm using an ELISA reader (SpectraFluor; Tecan), and the relative NO concentrations 
were calculated from a standard curve generated with NaNO2. 
 
Statistical analysis 
Data are expressedas themean± standarddeviation (SD) of at least two independent experiments. 
Statistical analysiswas performed by the “test of two means” using OpenStat program (http://www. 
statpages.org/miller/openstat/). P values < 0.05 were considered to be statistically significant. 
Results and Discussion 
 
Experimental infection of macrophages constitutes a particularly versatile model for assessing the 
immunoregulation that occurs during a cell-mediated response to an intracellular pathogen. Using 
obligate intracellular Leishmania parasites, the potential of EPs® 7630 for activating effective cytotoxic 
host defense mechanisms was evaluated. The elimination of the pathogen in macrophages was 
determined applying a flow cytometric (FACS) assay with transgenic L. major GFP. This elegant 
method allows to measure simultaneously antiparasitic effects, host cell viability, and immunological 
response markers at the single cell level [8]. Leishmania parasites exist as extracellular promastigotes 
within an insect vector and as intracellular amastigotes in phagocytes of vertebrate hosts. The latter 
form is of clinical and pharmacological importance. Due to the individual biological cycle, initial 
experiments were aimed at evaluating possible effects of the extract against promastigotes.  
 
Extracellular L. major GFP were incubated with 10 μg/mL of EPs® 7630 or 1% DMSO (vehicle 
control), respectively. After 48 h, the GFP signal as a measure of the viability of promastigotes was 
analyzed by FACS, while PI-positive events indicated dead parasites in a complementary manner. 
EPs® 7630 did not show any detectable effect on the viability of L. major GFP promastigostes (Fig. 1). 
On the other hand, exposure to the antileishmanial drug amphotericin B (1 μM) significantly reduced 
the GFP signal and increased, in parallel, the number of PI-positive (dead) cells. This finding 
demonstrates that EPs® 7630 does not directly affect the viability of L. major GFP promastigotes. 
Next, EPs® 7630 was tested for inducing microbicidal mechanisms in infected macrophages with an 
emphasis to reduce the parasitic burden. Activated murine BMMΦ are known to produce reactive 
oxygen and nitrogen species that exert potent antimicrobial activity. For example, there is ample 
evidence that NO produced by inducible NO synthase (iNOS) plays a decisive role as a microbicidal 
effector molecule in macrophage cytotoxicity towards a number of microorganisms including the 
Leishmania species [17–20]. That EPs® 7630 induces significant NO production in parasitized BMMΦ 
has already been demonstrated in a recent study but without any information on the rate of 
intracellular killing [7].  
 
In a first set of experiments, the effect of the known macrophagestimulating agents IFN-γ and LPS on 
the parasites’ viability and the host cells was tested and compared with that under EPs® 7630 
treatment (Fig. 2). For this, BMMΦ experimentally infected with L. major GFP promastigotes were 
rested for 24 h at 37°C to allow internalized parasites to transform into amastigotes. Although LPS (10 
ng/mL) alone is known to activate BMMΦ for intracellular leishmanicidal activity, the combination IFN-γ 
+ LPS proved to be highly effective andwas used in comparative experiments. When L. major GFP-
infected BMMΦ were exposed to rIFN-γ (100 U/mL) + LPS (10 ng/mL) or to rIFN-γ (100 U/mL) + EPs® 
7630 (10 μg/mL) for an additional 48 h, the resulting GFP signals were considerably reduced (ca. 6% 
and 9% GFP events, respectively) compared to the non-treated population (ca. 49% GFP events). In 
contrast, rIFN-γ alone was less effective in reducing the GFP signal (ca. 26% GFP events). Although 
priming of macrophages with IFN-γ alone does usually not result in any NO production, there was a 
clear stimulation of NO synthesis under our experimental condition (Fig. 3). This apparent discrepancy 
may be explained by the presence of a very low endotoxin contamination [21] in the rIFN-γ standard 
used in the current experiments, which was produced in gene-transfected E. coli. This conjecture finds 
support by previous studies using rIFN-γ of different batches with no detection of any NO production 
and missing effects on the survival rates of Leishmania parasites [8].  
 
This finding shows that EPs® 7630 significantly potentiates the killing of intracellular L. major GFP 
parasites in combination with rIFN-γ similar to that of LPS. Upon treatment of infected BMMΦ with 
amphotericin B (1 μM), a known antileishmanial agent [22], the GFP signal vanished rapidly without a 
concomitant stimulation of NO synthesis, indicating that the parasites had been killed directly (Figs. 2 
and 3). It should be noted that intracellular L. major GFP amastigotes show a characteristic GFP 
signal that correlates well with the relative number of BMMΦ still infected with viable parasites [8]. 
Importantly, host cell toxicity was less than 10% in all incubations as assessed by PI staining (Fig. 2). 
DMSO (0.5%) did not affect the survival rate of parasites and the NO production discussed below 
(data not shown).  
 
In cultures activated with rIFN-γ + LPS, a strong inverse correlation between NO levels and the 
intracellular survival rates of Leishmania parasites was noted [23]. Having in mind that EPs® 7630 
also showed an NO-inducing potential [7], attention was subsequently given to the question whether 
the enhanced parasite killing observed for the combination of rIFN-γ + EPs® 7630 similarly correlated 
with the NO production. For this reason, aliquots of the supernatants were collected for measuring NO 
concentrations (Griess assay), then the GFP signal of infected cells was determined by FACS 
analysis. As shown in Fig. 3, noninfected and infected BMMΦ produced relatively little detectable NO 
(0.6 μM). On the other hand, the combination rIFN-γ (100 U/ mlL) + LPS (10 ng/mL) strongly induced 
NO synthesis (ca. 28μM NO) compared with infected and rIFN-γ treated infected cells (ca. 7μM NO). 
Interestingly, the combination rIFN-γ (100 U/mL) + EPS® 7630 (10 ng/mL) was similarly effective with 
respect to NO-production (ca. 22 μM) and intracellular parasite kill (vide supra). Accordingly, the anti-
infective principle of EPS® 7630 appears to be strongly related to BMMΦ activation.  
 
In order to assess the role of iNOS, experiments were carried out in parallel with the known inhibitor L-
NMMA (Sigma Aldrich) [24]. The stereoisomer D-NMMA (Sigma Aldrich) is known to have no inhibitory 
effect on the enzyme and served as a negative control. As is evident from Fig. 4, inhibition of iNOS 
caused significantly lower NO levels and concomitantly increased the GFP signals, providing strong 
evidence for the crucial role of NO as a toxic effector molecule in the host defense to microbial 
infections and the pronounced NO-inducing capabilities of EPs® 7630.  
 
More detailed information about the induced NO release in killing amastigotes in EPs® 7630-activated 
BMMΦ was obtained from exposure to different concentrations of the extract (0.1– 10 μg/mL) in 
combination with rIFN-γ (100 U/mL). A strong inverse relationship between NO release and the 
intracellular survival of L. major GFP was evident (Fig. 5). Notably, treatment of infected BMMΦ with 
IFN-γ (100 U/mL) + EPs® 7630 (10 and 5 μg/ mL) was almost as effective as IFN-γ (100 U/mL) + LPS 
(10 ng/mL). Even at a concentration of 3 μg/mL EPs® 7630, a remarkable NO release (ca. 20 μM) 
was induced and the resulting GFP signal was reduced compared with untreated controls although 
this effect was not statistically significant.  
 
In a modified procedure, cell cultures were similarly incubated with EPs® 7630 in the absence of rIFN-
γ. As is obvious from Fig. 6, the NO-inducing effect was clearly less pronounced than in cultures 
exposed to the combination IFN-γ + EPs® 7630 but was still statistically significant at concentrations 
between 3 and 10 μg/ml when compared to vehicle treated controls. Similarly, events related to living 
(GFP-positive) parasites were reduced in a concentration-dependent manner in cultures containing 
EPs® 7630.  
 
One important function of IFN-γ, independent of the time of incubation [25], is its potential to sensitize 
macrophages to react more effectively when needed. The signal transduction is initiated via Toll-like 
receptors after pathogen recognition, for example, LPS, causing a stimulation of innate immune 
responses [25, 26]. The present data suggest that EPs® 7630 may similarly synergize with IFN-γ to 
induce an infectious-resistant state in neighboring cells. Comparable results have been reported for 
taxol which was shown to mimic LPS by triggering signal pathways via TLR-4 interaction [27, 28]. It 
may be speculated that EPs® 7630 also mediates anti-infective activities by TLR signalling. This is to 
be studied in the near future.  
 
EPs® 7630 has been shown to be an efficient herbal medicine for the treatment of upper respiratory 
tract infections, e.g. bronchitis. The causative pathogens are predominantly viruses including the 
respiratory syncytial virus, Coxsackie, influenza, para-influenza, and ECHO viruses, although bacterial 
infections may play a role. The destabilized defense mechanisms resulting from a viral infection can 
clear the way for a secondary bacterial infection. Induction of nonspecific host defense mechanisms 
against a number of pathogens including viruses is intimately related to the IFN-system. Both type I 
and type II IFNs can protect cells from viral infections, while IFN-γ functions as the major macrophage 
activating factor. In light of the documented efficacy of EPs® 7630 in the treatment of respiratory 
diseases with primary viral infections, we investigated this special extract for its direct antiviral 
potential and for its capacity to induce the production of antiviral components in BMMΦ using a 
fibroblast-virus protection assay.  
 
After 24 h of incubation, supernatants of EPs® 7630-activated BMMΦ were analyzed for their capacity 
to protect L929 fibroblasts from the CPE of EMCV using crystal violet as a staining reagent for 
protected cells. LPS (1 ng/mL) served as a positive control [29, 30], while untreated BMMΦ and 
DMSO (0.5%) were used as negative controls (Fig. 7). In parallel, NO production was measured as an 
indicator for cell activation and as a possible contributing factor to the overall antiviral activity [31]. 
Dead BMMΦ (< 10 in all experiments) were quantified by FACS using PI-staining [14]. The 
cytoprotective effect was compared to that of rIFN-γ (100 U/mL). Antiviral protection was expressed in 
U/mL, defined as the reciprocal value of the supernatant dilution that would inhibit 50% of the CPE 
induced by EMCV in L929 cells. These values were correlated with the IFN standard to account for 
any fluctuation in assay sensitivity.  
 
Prominent cytoprotective effects were observed for EPs® 7630 in a concentration-dependent manner 
(1–10 μg/mL) (Fig. 7). Conspicuously, when BMMΦ were incubated with 10 μg/mL of EPs® 7630, the 
resulting antiviral activity (ca. 80 U/mL) was similar to that of the LPS response. However, the induced 
NO production was remarkably enhanced in EPs® 7630-stimulated cell cultures, but dropped 
noticeably close to detection limits when exposed to a lower sample concentration (5 μg/mL). On the 
other hand, EPs® 7630 at this concentration still exerted fairly high cytoprotective effects (ca. 35 
U/mL) in the virus protection assay, suggesting that different cellular defense mechanisms are 
activated independently. The NO production induced by EPs® 7630 does not seem to represent a 
major contributing factor to the overall antiviral activity. EPs® 7630 on its own did not induce any 
cytoprotective effects when directly added to L929 fibroblasts (Fig. 8).  
 
Known antiviral factors are members of the IFN family classified in type 1 and type 2 interferons 
according to receptor specificity and sequence homology [20]. The functional virus protection assay 
used in this study does not discriminate between IFN-α, IFN- β, and IFN-γ. In order to gain insight into 
the underlying antiviral principle,we tried to measure distinct IFN proteins by using com-mercially 
available ELISA kits. Surprisingly, measurement of IFN proteins proved to be invariably unsuccessful 
in a series of experiments. The failure to detect any IFN proteins by applying ELISAs may be 
rationalized by the production of IFN quantities below the detection limits of the assays (IFN-α: 16 
pg/mL, IFN-β: 16 pg/mL, and IFN-γ: 40 pg/mL, respectively). On the other hand, the virus protection 
assay represents a very sensitive functional method. Only very few IFN molecules may readily interact 
with receptors, triggering signal transduction pathways for antiviral responses [32]. Future studies are 
required to support this conjecture by using highly sensitive methods such as quantitative PCR 
analysis. Another possible explanation may be that IFN molecules of different types may act 
synergistically in the protection of L929 cells. Besides, other antiviral factors such as type III IFN [33] 
or eicosanoids [34, 35] may play a role in the control of viral infection. Very recent work showed that 
EPs® 7630 suppressed rather than stimulated the synthesis of eicosanoids in calciumionophore 
stimulated human granulocytes [36], rendering their implication less likely.  
 
Using BMMΦ experimentally infected with L. major GFP, incubation with EPs® 7630 induced release 
of NO in a concentration-dependent manner and significantly reduced the parasitic burden at relatively 
low concentrations. The assessment of the killing of the pathogen carried out at single cell levels 
reaffirmed the antiinfectious potential of this herbal medicine, previously concluded from diverse 
functional assays. The mode of action of activated cytotoxic defense mechanisms, e.g., NO 
production, on intracellular pathogens remained unknown. The present data provide convincing 
evidence of the effectiveness of the immune response induced in infected cells.  
 
Since respiratory tract infections are frequently caused by viruses, the modulatory potential of EPs® 
7630 as assessed in a fibroblast/ EMCV protection assay deserves to be explicitly mentioned. 
Supernatants of EPs® 7630-activated BMMΦ showed prominent cytoprotective effects. Although it 
appears reasonable to relate the antiviral activity to the IFN system, detection of IFN molecules using 
ELISA kits were unsuccessful, possibly due to very low amounts. Conspicuously, when L929 cells 
were directly incubated with the extract, inhibition of the cytopathic effect of the virus on fibroblasts 
was not evident and in contrast with similar incubations using an IFN-γ standard.  
 
Further studies are needed to identify the signalling pathway and the antiviral components. A closer 
look into the composition of EPs® 7630 remains a challenge towards a better understanding of the 
responsible biologically active substances. 
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Figures 
 
Figure 1. EPs® 7630 per se did not kill L. major GFP promastigotes. Propidium iodide-positive (dead) 
vs. GFP-positive (living) parasites: A Untreated Leishmania parasites, B promastigotes (1.0 x 106) 
treated with 10 Mg/mL of EPs® 7630, C DMSO (1 %) for 48 h, and D with amphotericin B (1 MM/10 
MM) for 24 h, respectively. One of two examples with similar results is shown. 
 
 
 
 
 
 
 
Figure 2. Effect of EPs® 7630 in the presence of IFN-y on the viability of L. major GFP amastigotes in 
infected BMM<t> as assessed by FACS analysis after 48 h incubation. A noninfected, B infected cells, 
C infected cells + IFN-y (100U/mL), D infected cells + IFN-y (100 U/mL)/LPS (10 ng/mL), E infected 
cells + IFN-y (100 U/ml)/EPs® 7630 (10ug/mL), F infected cells + amphotericin B (1 uM). The depicted 
experiment is one out of six independent experiments with similar results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Relative survival rates of intracellular L. major GFP parasites (GFPpositive events) and 
concomitant NO production as assessed by FACS analysis and in the Griess assay, respectively. A 
non-infected, B infected cells, C infected cells + IFN-γ (100 U/mL), D infected cells + IFN-γ (100 
U/mL)/LPS (10 ng/mL), E infected cells + IFN-γ (100 U/mL)/EPs® 7630 (10 μg/mL), F infected cells + 
amphothericin B. The values (mean ± SD) are derived from six independent experiments [p < 0.05; 
GFP-signal (*), NO production (*)]. 
 
 
 
 
 
 
Figure 4. Relative survival rates of intracellular L. major GFP parasites (GFPpositive events; FACS 
analysis) and concomitant NO production (Griess assay) in infected BMMΦ stimulated in the presence 
and absence of L-NMMA and D-NMMA (each at 500 μM), respectively. The depicted experiment is 
one of two independent experiments with similar results. 
 
 
 
 
 
 
 
 
Figure 5. Relative survival rates of intracellular L. major GFP parasites (GFPpositive events; FACS 
analysis) and concomitant NO production (Griess assay) in infected BMMΦ treated with EPs® 7630 
(10–0.1 μg/mL) + IFN-γ (100 U/mL). Control experiments included the exposure of cells to IFN-γ 
(100 U/mL) and IFN-γ (100 U/mL)+ LPS (10 ng/mL), respectively. The values (mean ± SD) are derived 
from six independent experiments [p < 0.05; GFPsignal (*), NO production (*)]. 
 
 
 
 
Figure 6. Relative survival rates of intracellular L. major GFP parasites (GFPpositive events; FACS 
analysis) and concomitant NO production (Griess assay) in infected BMMΦ treated with EPs® 7630 
(10–0.1 μg/mL). IFN-γ (100 U/mL) + LPS (10 ng/mL) stimulated cells served as positive and untreated 
cells as negative controls. The values (mean ± SD) are derived from six independent experiments (p < 
0.05; NO production [*]). 
 
 
 
 
 
 
Figure 7. Fibroblast-virus protection assay. A Antiviral effects of an IFN-γ standard (100 U/mL) and 
supernatants from BMMΦtreated with EPs® 7630 (10 μg/mL) shown by serial dilutions in microtiter 
plates and crystal violet staining. B Cytoprotective effects of EPs® 7630 as assessed in the fibroblast/ 
EMCV protection assay and simultaneous measurement of NO production (Griess assay).The values 
(mean ± SD) are derived from three independent experiments [p < 0.05; NO production (*), antiviral 
activity (*)]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Antiviral effects of an IFN-y standard (100 U/mL) and EPs® 7630 (10 ug/mL) on L929 cells 
shown by serial dilutions in microtiter plates and crystal violet staining following direct incubations. 
 
 
 
 
